221 related articles for article (PubMed ID: 20147395)
1. Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu.
Goffinet C; Homann S; Ambiel I; Tibroni N; Rupp D; Keppler OT; Fackler OT
J Virol; 2010 Apr; 84(8):4089-94. PubMed ID: 20147395
[TBL] [Abstract][Full Text] [Related]
2. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor.
Goffinet C; Allespach I; Homann S; Tervo HM; Habermann A; Rupp D; Oberbremer L; Kern C; Tibroni N; Welsch S; Krijnse-Locker J; Banting G; Kräusslich HG; Fackler OT; Keppler OT
Cell Host Microbe; 2009 Mar; 5(3):285-97. PubMed ID: 19286137
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.
Pujol FM; Laketa V; Schmidt F; Mukenhirn M; Müller B; Boulant S; Grimm D; Keppler OT; Fackler OT
J Virol; 2016 Aug; 90(15):6709-6723. PubMed ID: 27170757
[TBL] [Abstract][Full Text] [Related]
5. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking.
Mitchell RS; Katsura C; Skasko MA; Fitzpatrick K; Lau D; Ruiz A; Stephens EB; Margottin-Goguet F; Benarous R; Guatelli JC
PLoS Pathog; 2009 May; 5(5):e1000450. PubMed ID: 19478868
[TBL] [Abstract][Full Text] [Related]
6. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
[TBL] [Abstract][Full Text] [Related]
7. Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue.
Schindler M; Rajan D; Banning C; Wimmer P; Koppensteiner H; Iwanski A; Specht A; Sauter D; Dobner T; Kirchhoff F
Retrovirology; 2010 Jan; 7():1. PubMed ID: 20078884
[TBL] [Abstract][Full Text] [Related]
8. Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.
Yao W; Yoshida T; Hashimoto S; Takeuchi H; Strebel K; Yamaoka S
J Virol; 2020 Jan; 94(2):. PubMed ID: 31666374
[TBL] [Abstract][Full Text] [Related]
9. The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu.
Andrew AJ; Miyagi E; Kao S; Strebel K
Retrovirology; 2009 Sep; 6():80. PubMed ID: 19737401
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction.
Schmidt S; Fritz JV; Bitzegeio J; Fackler OT; Keppler OT
mBio; 2011; 2(3):e00036-11. PubMed ID: 21610122
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/Tetherin.
Fritz JV; Tibroni N; Keppler OT; Fackler OT
Virology; 2012 Mar; 424(1):33-44. PubMed ID: 22222210
[TBL] [Abstract][Full Text] [Related]
12. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.
Vigan R; Neil SJ
J Virol; 2010 Dec; 84(24):12958-70. PubMed ID: 20926557
[TBL] [Abstract][Full Text] [Related]
13. Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin.
Vigan R; Neil SJ
J Virol; 2011 Oct; 85(19):9737-48. PubMed ID: 21775465
[TBL] [Abstract][Full Text] [Related]
14. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion.
Miyagi E; Andrew AJ; Kao S; Strebel K
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2868-73. PubMed ID: 19196977
[TBL] [Abstract][Full Text] [Related]
15. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.
Kueck T; Neil SJ
PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182
[TBL] [Abstract][Full Text] [Related]
16. CD317/tetherin is enriched in the HIV-1 envelope and downregulated from the plasma membrane upon virus infection.
Habermann A; Krijnse-Locker J; Oberwinkler H; Eckhardt M; Homann S; Andrew A; Strebel K; Kräusslich HG
J Virol; 2010 May; 84(9):4646-58. PubMed ID: 20147389
[TBL] [Abstract][Full Text] [Related]
17. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.
Neil SJ; Zang T; Bieniasz PD
Nature; 2008 Jan; 451(7177):425-30. PubMed ID: 18200009
[TBL] [Abstract][Full Text] [Related]
18. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants.
McNatt MW; Zang T; Hatziioannou T; Bartlett M; Fofana IB; Johnson WE; Neil SJ; Bieniasz PD
PLoS Pathog; 2009 Feb; 5(2):e1000300. PubMed ID: 19214216
[TBL] [Abstract][Full Text] [Related]
19. The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation.
Janvier K; Pelchen-Matthews A; Renaud JB; Caillet M; Marsh M; Berlioz-Torrent C
PLoS Pathog; 2011 Feb; 7(2):e1001265. PubMed ID: 21304933
[TBL] [Abstract][Full Text] [Related]
20. Ion channel activity of HIV-1 Vpu is dispensable for counteraction of CD317.
Bolduan S; Votteler J; Lodermeyer V; Greiner T; Koppensteiner H; Schindler M; Thiel G; Schubert U
Virology; 2011 Jul; 416(1-2):75-85. PubMed ID: 21601230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
